Success Stories: EB-1A Approved for Polymeric Biomaterials Researcher Advancing Biomaterials Design

Client’s Testimonial:

“Thank you!!! I really appreciate all your help with my case.”

On August 6^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Investigator in the field of Polymeric Biomaterials (Approval Notice).

General Field: Polymeric Biomaterials

Position at the Time of Case Filing: Research Investigator

Country of Origin: China

State of Residence at the Time of Filing: Michigan

Approval Notice Date: August 6^th, 2025

Processing Time: 1 year, 5 months, 11 days

Case Summary:

We are pleased to share the success story of an EB-1A petition approval granted to a research investigator whose pioneering work in polymeric biomaterials has led to breakthroughs in gene and drug delivery systems, tissue-engineering scaffolds, and antimicrobial polymer design.

Research Focus and Contributions

The petition showcased a versatile research program in polymeric biomaterials, beginning with the design of star-shaped gene vectors that combine high transfection efficiency and biocompatibility. It highlighted the synthesis of biodegradable polymers for controlled drug release, the creation of nano-fibrous scaffolds to support tissue regeneration, and the development of antimicrobial polymer coatings to protect medical devices from infection. Collectively, these innovations demonstrate the client’s ability to translate advanced polymer science into real-world biomedical solutions.

Research Impact and Metrics

To demonstrate extraordinary ability, the petition assembled key quantitative metrics:

15 journal articles documenting first-in-field advances in polymeric biomaterials.
592 citations, placing the researcher among the top 1% most-cited authors in polymer science.
Completed at least 26 invited manuscript reviews for leading journals, confirming recognized authority.

Here is an anonymized excerpt from a recommendation letter that underscores the practical impact of his work:

“[Client’s] advanced knowledge of polymer synthesis and characterization led to the introduction of N-halamine-based polymers that, when incorporated into commercial biomedical materials, demonstrated complete antimicrobial effects against both planktonic bacteria and biofilms through sustained release of biocidal agents.”

Demonstrating Extraordinary Ability

The petition provided evidence of independent adoption of the client’s polymeric tools by global research teams and extensive peer review and editorial service for top journals. A comprehensive merits determination confirmed that the client ranks among the very small percentage at the pinnacle of polymeric biomaterials research.

Well Positioned for Continued Innovation

The petition documented the client’s advanced training (Ph.D. in polymer science), extensive postdoctoral and research investigator experience, and leadership of multidisciplinary collaborations to translate polymeric biomaterials into clinical and industrial applications, establishing a strong foundation for future breakthroughs.

Approval and Outcome

Filed on February 26, 2024, and approved on August 6, 2025, in 1 year, 5 months, and 11 days without any RFE (request for evidence), this EB-1A success underscores the United States’ commitment to retaining exceptional talent in critical scientific fields. NAILG is proud to have guided this client through a seamless EB-1A process and looks forward to supporting ongoing contributions to biomaterials innovation and public health.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.